Inhibikase switches auditor to Deloitte for 2026
Rhea-AI Filing Summary
Inhibikase Therapeutics, Inc. (IKT) reported that its Audit Committee dismissed CohnReznick LLP as independent registered public accounting firm on August 21, 2026, and, effective immediately thereafter, appointed Deloitte & Touche LLP as the new independent registered public accounting firm for the fiscal year ending December 31, 2026. CohnReznick’s audit reports for the years ended December 31, 2025 and 2024 contained no adverse opinions, disclaimers, or qualifications, and the company states there were no disagreements on accounting principles, financial disclosure, or audit scope. CohnReznick had previously advised that a material weakness in internal control over financial reporting existed during the year ended December 31, 2024; this was earlier disclosed and described as remediated by prior management by the quarter ended September 30, 2024. Other than that reportable event, the company reports no additional reportable events during 2025, 2024, or subsequent interim periods.
Positive
- Material weakness previously remediated: A material weakness in internal control over financial reporting identified during the fiscal year ended December 31, 2024 was disclosed earlier and is described as having been remediated by prior management by the quarter ended September 30, 2024.
Negative
- History of material weakness in internal controls: The prior auditor advised that a material weakness in internal control over financial reporting existed during the fiscal year ended December 31, 2024, which was significant enough to be a reportable event under Item 304(a)(1)(v) of Regulation S-K.
Filing Explained
The filing adds a procedural checkpoint: CohnReznick’s
8-K Event Classification
2 items: 4.01, 9.01
2 items
Item 4.01
Changes in Registrant's Certifying Accountant
Governance
The company changed its independent auditing firm, which may involve disagreements on accounting matters.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Auditor dismissal date: August 21, 2026
New auditor fiscal year: Fiscal year ending December 31, 2026
Fiscal year end: December 31, 2025
+3 more
6 metrics
Auditor dismissal date
August 21, 2026
Date the Audit Committee approved dismissal of CohnReznick LLP
New auditor fiscal year
Fiscal year ending December 31, 2026
Engagement period for Deloitte & Touche LLP
Fiscal year end
December 31, 2025
One of the years covered by CohnReznick’s audit reports without adverse opinions
Fiscal year end
December 31, 2024
Year in which a material weakness in internal control over financial reporting existed
Quarter of remediation disclosure
Quarter ended September 30, 2024
Quarterly Report in which remediation of the material weakness was disclosed
CEO signature date
August 26, 2026
Date the report was signed by Chief Executive Officer Mark Iwicki
Key Terms
independent registered public accounting firm, material weakness, internal control over financial reporting, reportable event, +1 more
5 terms
independent registered public accounting firm financial
"dismissal of CohnReznick LLP as the Company’s independent registered public accounting firm"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
material weakness financial
"a material weakness existed in the Company’s internal control over financial reporting"
A material weakness is a significant flaw in the systems and checks a company uses to ensure its financial reports are accurate, meaning errors or fraud could happen and not be caught. For investors it matters because it raises the risk that reported results are unreliable—similar to finding a hole in a ship’s hull—potentially leading to corrected financials, regulatory action, reduced trust, and negative effects on stock value and borrowing costs.
internal control over financial reporting financial
"a material weakness existed in the Company’s internal control over financial reporting"
Internal control over financial reporting is a company’s system of procedures and checks designed to make sure its financial statements are accurate and complete, like a set of guardrails and verification steps that catch mistakes or fraud before numbers are published. Investors care because strong controls make reported results more trustworthy, lower the risk of surprise restatements or regulatory problems, and give greater confidence when valuing the company or comparing it to peers.
reportable event regulatory
"which constituted a reportable event as defined in Item 304(a)(1)(v)"
Regulation S-K regulatory
"as defined in Item 304(a)(1)(iv) of Regulation S-K"
A set of U.S. Securities and Exchange Commission rules that tell public companies which narrative and qualitative details must be disclosed in filings, such as risk factors, management discussion, executive pay, legal proceedings and business description. Think of it as a standardized checklist or blueprint that ensures investors get the same types of background information from every company so they can compare risks, management quality and strategy before making investment decisions.
FAQ
What auditor change did Inhibikase Therapeutics (IKT) announce?
The Audit Committee dismissed CohnReznick LLP as independent registered public accounting firm on August 21, 2026, and appointed Deloitte & Touche LLP as the new independent registered public accounting firm for the fiscal year ending December 31, 2026.
Did CohnReznick’s audit opinions on IKT’s 2025 and 2024 financials contain any qualifications?
CohnReznick’s audit reports on Inhibikase Therapeutics’ 2025 and 2024 consolidated financial statements contained no adverse opinion, disclaimer of opinion, or qualification related to uncertainty, audit scope, or accounting principles.
Were there any disagreements between IKT and CohnReznick before the auditor’s dismissal?
The company states that during the fiscal years ended December 31, 2025 and 2024 and the subsequent interim period through the dismissal date, there were no disagreements with CohnReznick on accounting principles, financial statement disclosure, or auditing scope or procedure.
What internal control issue did Inhibikase Therapeutics (IKT) disclose?
For the fiscal year ended December 31, 2024, CohnReznick advised that a material weakness in internal control over financial reporting existed, which the company had previously disclosed as a reportable event under Regulation S-K.
Has the previously identified material weakness at IKT been addressed?
The company reports that the material weakness identified during the 2024 fiscal year was remediated by prior management and that this remediation was disclosed in the Quarterly Report on Form 10-Q for the quarter ended September 30, 2024.
What period will Deloitte & Touche LLP audit for IKT?
Deloitte & Touche LLP has been appointed as Inhibikase Therapeutics’ independent registered public accounting firm for the fiscal year ending December 31, 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
